



Supplemental Fig. 1. **A** Violin plots of normalized RNA counts and features in scRNA-seq dataset. **B** Dot plot of zscores generated for scRNA-seq cell type clusters. **C** Feature plots of zscores for cell type clusters, generated by FindAllMarkers, using top 5 statistically significant (avg. logFC >0.5, adjusted P value <0.05, Bonferroni correction) genes per cell type. **D** Feature plot of IFNG expression split by disease state. **E** Feature plot of CTSS expression.




Supplemental Fig. 2. A Top unique and shared statistically significant (avg. logFC >0.5, adjusted P value <0.05, Bonferroni correction) DE genes in modulated smooth muscle cells in CAV and CAD relative to control samples. **B** UMAP embedding plot of subclustered modulated smooth muscle cells and **C** the respective composition plot. **D** Pathway analysis performed using top 25 statistically significant DE genes from CAV and CAD samples. **E** Top unique and shared statistically significant DE genes in fibroblasts in CAV and CAD relative to control samples. **F** UMAP embedding plot of subclustered fibroblasts and **F** the respective composition plot.


A




B



C



D



Response of EIF2AK1 (HRI) to Heme Deficiency

Interferon Alpha/Beta Signaling

Interferon Gamma Signaling


Response of EIF2AK4 (GCN2) to Amino Acid Deficiency

Interferon Signaling


CAD top pathways




E




F




Supplemental Fig. 3. **A** Top unique and shared statistically significant (avg. logFC >0.5, adjusted P value <0.05, Bonferroni correction) DE genes in endothelial cells in CAV and CAD relative to control samples. **B** Pathway analysis performed using top 25 statistically significant DE genes in endothelial cells in CAV and CAD. **C** UMAP embedding plot of subclustered endothelial cell states and **D** the respective composition plot. **E** Feature plot of CAV and CAD endothelial module scores generated from top 25 statistically significant DE genes relative to control samples. **F** Dot plot of top DE gene expression in endothelial cell states.



Supplemental Fig. 4. **A** UMAP embedding plot of scRNA-seq object containing high-resolution, subclustered myeloid and stromal cell states. **B** UMAP embedding plot of merged spatial object with annotated spatial niches. **C** DimPlot of annotated spatial niches on tissue slices and **D** composition plot of spatial niches in CAV1, CAV2, CAV3 and CAV4. **E** Normalized RNA counts in spatial samples. **F** Histopathology (H&E) of CAV3 and **G** CAV4.




Supplemental Fig. 5. **A** First-type Seurat deconvolution results for CAV3 and **B** CAV4. **C** Second-type Seurat deconvolution results for CAV1, CAV2, CAV3, and CAV4. **D** Spatial feature plot of SMC, **E** endothelial, and **F** fibroblast gene signatures to validate spatial deconvolution results



Supplemental Fig. 6. **A** Immunostaining of TNFRSF11B (modulated SMC) and Phospho-Stat1 (IFN signaling) within the neointima of CAV1. **B** Immunostaining of aSMA (SMC) and CD31 (endothelial cell) within the neointima. **C** Spatial feature plot of tertiary lymphoid organ genes and **D** immunofluorescence staining for CD4 (CD4+ T cell) and PNAd (peripheral node addressin) in CAV1 **E** Spatial feature plot of T helper 1 (Th1) and CD8 (CD8+ T cell) gene signature scores in CAV1 **F** Immunofluorescence staining for CD68 and CTSS (Cathepsin S) within the neointima of a CAV sample. **E** SPOTlight spatial interaction plots for CAV2, CAV3, and CAV4 samples.

A



Supplemental Fig. 7. A MultiNicheNetr top 50 predicted ligand:receptor interactions in CAD scRNA-seq samples.